Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health MedicinesBusiness Wire • 07/19/22
Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property PortfolioBusiness Wire • 07/13/22
Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022PRNewsWire • 05/24/22
Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022PRNewsWire • 05/17/22
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to ShareholdersPRNewsWire • 05/11/22
Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ETPRNewsWire • 05/05/22
Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common StockPRNewsWire • 05/03/22
Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022PRNewsWire • 04/06/22
Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business UpdatePRNewsWire • 03/31/22
Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent ApplicationPRNewsWire • 03/29/22
Enveric Biosciences touts the publication of four patent applications for psychedelic-inspired drug candidatesProactive Investors • 03/15/22
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug CandidatesPRNewsWire • 03/15/22
Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022PRNewsWire • 03/03/22
Enveric Biosciences files portfolio of patent applications for tryptamine derivativesProactive Investors • 03/01/22
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based MoleculesPRNewsWire • 03/01/22
Enveric Biosciences collaborates with University of Calgary to establish clinical trial for EVM-101 in cancer related distressProactive Investors • 02/17/22
Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related DistressPRNewsWire • 02/17/22
Enveric Biosciences announces closing of $10M underwritten public offeringProactive Investors • 02/15/22